A study by De Beaumont and colleagues demonstrated that AD patients, who are carriers of APOE ε4 and BCHE K-variant, have an earlier age of onset, accelerated cognitive decline and better response to donepezil therapy [227]. This evidence concerns the gene APOE and Alzheimer disease.